Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Sunitinib (SU11248; NSC 736511) in Patients With Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

NCT00388037 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00388037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00388037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Sunitinib (SU11248; NSC 736511) in Patients With Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2007
Completion date
January 31, 2012
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent fallopian tube cancer, recurrent ovarian epithelial cancer, recurrent primary peritoneal cavity cancer, stage iiia fallopian tube cancer, stage iiia ovarian epithelial cancer, stage iiia primary peritoneal cavity cancer, stage iiib fallopian tube cancer, stage iiib ovarian epithelial cancer, stage iiib primary peritoneal cavity cancer, stage iiic fallopian tube cancer, stage iiic ovarian epithelial cancer, stage iiic primary peritoneal cavity cancer, stage iv fallopian tube cancer, stage iv ovarian epithelial cancer, stage iv primary peritoneal cavity cancer